Loredana Cleris

List of Publications by Year
in descending order

46 papers	2,472 citations	257450 24 h-index	243625 44 g-index
47 all docs	47 docs citations	47 times ranked	3750 citing authors

#	Article	IF	Citations
1	Gene signatures of circulating breast cancer cell models are a source of novel molecular determinants of metastasis and improve circulating tumor cell detection in patients. Journal of Experimental and Clinical Cancer Research, 2022, 41, 78.	8.6	15
2	Senescent Thyrocytes, Similarly to Thyroid Tumor Cells, Elicit M2-like Macrophage Polarization In Vivo. Biology, 2021, 10, 985.	2.8	3
3	The Detection and Morphological Analysis of Circulating Tumor and Host Cells in Breast Cancer Xenograft Models. Cells, 2019, 8, 683.	4.1	21
4	Targeting COPZ1 non-oncogene addiction counteracts the viability of thyroid tumor cells. Cancer Letters, 2017, 410, 201-211.	7.2	15
5	Sodium 4-Carboxymethoxyimino-(4-HPR) a Novel Water-Soluble Derivative of 4-Oxo-4-HPR Endowed with In Vivo Anticancer Activity on Solid Tumors. Frontiers in Pharmacology, 2017, 8, 226.	3.5	5
6	Waterâ€soluble derivatives of 4â€oxoâ€<i>N</i>â€(4â€hydroxyphenyl) retinamide: synthesis and biological activity. Chemical Biology and Drug Design, 2016, 88, 608-614.	3.2	2
7	Immunomodulatory Factors Control the Fate of Melanoma Tumor Initiating Cells. Stem Cells, 2016, 34, 2449-2460.	3.2	21
8	Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade. Oncotarget, 2016, 7, 3947-3965.	1.8	45
9	BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts. Leukemia, 2014, 28, 1861-1871.	7.2	48
10	S100A11 Overexpression Contributes to the Malignant Phenotype of Papillary Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1591-E1600.	3.6	40
11	Induction of death receptor 5 expression in tumor vasculature by perifosine restores the vascular disruption activity of TRAIL-expressing CD34+ cells. Angiogenesis, 2013, 16, 707-722.	7.2	5
12	Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts. Leukemia, 2013, 27, 1677-1687.	7.2	26
13	D Quantification of Tumor Vasculature in Lymphoma Xenografts in NOD/SCID Mice Allows to Detect Differences among Vascular-Targeted Therapies. PLoS ONE, 2013, 8, e59691.	2.5	9
14	Sorafenib Inhibits Lymphoma Xenografts by Targeting MAPK/ERK and AKT Pathways in Tumor and Vascular Cells. PLoS ONE, 2013, 8, e61603.	2.5	34
15	AMPK activators inhibit the proliferation of human melanomas bearing the activated MAPK pathway. Melanoma Research, 2012, 22, 341-350.	1.2	38
16	TIMP3 regulates migration, invasion and in vivo tumorigenicity of thyroid tumor cells. Oncogene, 2011, 30, 3011-3023.	5.9	78
17	Human CD34+ cells engineered to express membrane-bound tumor necrosis factorâ€"related apoptosis-inducing ligand target both tumor cells and tumor vasculature. Blood, 2010, 115, 2231-2240.	1.4	32
18	IGFBP7: an oncosuppressor gene in thyroid carcinogenesis. Oncogene, 2010, 29, 3835-3844.	5.9	69

#	Article	IF	Citations
19	Colorectal Tumors Are Effectively Eradicated by Combined Inhibition of Î²-Catenin, KRAS, and the Oncogenic Transcription Factor ITF2. Cancer Research, 2010, 70, 7253-7263.	0.9	45
20	Valproic acid enhances bosutinib cytotoxicity in colon cancer cells. International Journal of Cancer, 2009, 124, 1990-1996.	5.1	29
21	Metallothionein 1G acts as an oncosupressor in papillary thyroid carcinoma. Laboratory Investigation, 2008, 88, 474-481.	3.7	60
22	Characterization of compound 584, an Abl kinase inhibitor with lasting effects. Haematologica, 2008, 93, 653-661.	3.5	14
23	IFN-Î³ Enhances the Antimyeloma Activity of the Fully Human Antiâ€"Human Leukocyte Antigen-DR Monoclonal Antibody 1D09C3. Cancer Research, 2007, 67, 3269-3275.	0.9	18
24	Placental Growth Factor-1 Potentiates Hematopoietic Progenitor Cell Mobilization Induced by Granulocyte Colony-Stimulating Factor in Mice and Nonhuman Primates. Stem Cells, 2007, 25, 252-261.	3.2	12
25	Antitumor Activity of Human CD34+Cells Expressing Membrane-Bound Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand. Human Gene Therapy, 2006, 17, 1225-1240.	2.7	33
26	CD52 antigen expressed by malignant plasma cells can be targeted by alemtuzumab in vivo in NOD/SCID mice. Experimental Hematology, 2006, 34, 721-727.	0.4	25
27	In vitro and In vivo Activity of SKI-606, a Novel Src-Abl Inhibitor, against Imatinib-Resistant Bcr-Abl+ Neoplastic Cells. Cancer Research, 2006, 66, 11314-11322.	0.9	352
28	The Antiâ€"Human Leukocyte Antigen-DR Monoclonal Antibody 1D09C3 Activates the Mitochondrial Cell Death Pathway and Exerts a Potent Antitumor Activity in Lymphoma-Bearing Nonobese Diabetic/Severe Combined Immunodeficient Mice. Cancer Research, 2006, 66, 1799-1808.	0.9	37
29	Inhibition of RET tyrosine kinase by SU5416. Journal of Molecular Endocrinology, 2006, 37, 199-212.	2.5	68
30	Antitumor Activity of Human CD34+Cells Expressing Membrane-Bound Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand. Human Gene Therapy, 2006, .	2.7	0
31	Mobilization of primitive and committed hematopoietic progenitors in nonhuman primates treated with defibrotide and recombinant human granulocyte colony-stimulating factor. Experimental Hematology, 2004, 32, 68-75.	0.4	7
32	Age- and irradiation-associated loss of bone marrow hematopoietic function in mice is reversed by recombinant human growth hormone. Experimental Hematology, 2004, 32, 171-178.	0.4	48
33	Bcl-XL down-regulation suppresses the tumorigenic potential of NPM/ALK in vitro and in vivo. Blood, 2004, 103, 2787-2794.	1.4	30
34	Effect of imatinib on haematopoietic recovery following idarubicin exposure. Leukemia, 2003, 17, 298-304.	7.2	11
35	Role of TFG sequences outside the coiled-coil domain in TRK-T3 oncogenic activation. Oncogene, 2003, 22, 807-818.	5.9	28
36	Selective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cells. Cancer Letters, 2002, 175, 17-25.	7.2	441

#	Article	IF	Citations
37	Defibrotide in combination with granulocyte colony-stimulating factor significantly enhances the mobilization of primitive and committed peripheral blood progenitor cells in mice. Cancer Research, 2002, 62, 6152-7.	0.9	18
38	Decrease in drug accumulation and in tumour aggressiveness marker expression in a fenretinide-induced resistant ovarian tumour cell line. British Journal of Cancer, 2001, 84, 1528-1534.	6.4	33
39	Growth-inhibitory effect of STI571 on cells transformed by theCOL1A1/PDGFB rearrangement. International Journal of Cancer, 2001, 92, 354-360.	5.1	114
40	Therapeutic effects of the combination of fenretinide and all-trans-retinoic acid and of the two retinoids with cisplatin in a human ovarian carcinoma xenograft and in a cisplatin-resistant sub-line. European Journal of Cancer, 2000, 36, 2411-2419.	2.8	22
41	In Vivo Eradication of Human BCR/ABL-Positive Leukemia Cells With an ABL Kinase Inhibitor. Journal of the National Cancer Institute, 1999, 91, 163-168.	6.3	341
42	Role of retinoic acid receptor overexpression in sensitivity to fenretinide and tumorigenicity of human ovarian carcinoma cells. , 1999, 81, 829-834.		42
43	Induction of apoptosis by fenretinide (4HPR) in human ovarian carcinoma cells and its association with retinoic acid receptor expression. , 1996, 65, 491-497.		106
44	Postsurgical adjuvant chemoimmunotherapy with recombinant interleukin-2 and 1,3-bis-(2-chloroethyl)-1-nitrosurea on spontaneous metastases of a non-immunogenic murine tumour. Cancer Immunology, Immunotherapy, 1992, 34, 383-388.	4.2	4
45	Effect of verapamil on doxorubicin activity and pharmacokinetics in mice bearing resistant and sensitive solid tumors. Cancer Chemotherapy and Pharmacology, 1988, 21, 329-36.	2.3	19
46	Verapamil potentiation of doxorubicin resistance development in B16 melanoma cells both in vitro and in vivo. British Journal of Cancer, 1988, 57, 343-347.	6.4	8